Tirzepatide·Eli Lilly·Injectable pen

Zepbound

Zepbound® is an FDA-approved once-weekly injectable tirzepatide pen manufactured by Eli Lilly, FDA-approved in November 2023 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is administered once weekly across a 2.5mg to 15mg dose range. Weight Method does not dispense or prescribe brand-name Zepbound®. Our prescribing providers issue patient-specific prescriptions for compounded tirzepatide, dispensed by U.S.-licensed 503A compounding pharmacies. Compounded tirzepatide is not FDA-approved.

2.5mg5mg7.5mg10mg12.5mg15mgOnce weekly
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Zepbound is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated June 2026Medically reviewed by licensed providers

Zepbound (tirzepatide) is an FDA-approved GLP-1 medication for weight loss; in trials of the brand-name product, patients lost an average of 15-22% of their body weight. Weight Method does not dispense brand-name Zepbound — it offers compounded tirzepatide, prescribed by licensed providers, from $199/month with virtual consultations and direct shipping.

Key Fact

Zepbound (tirzepatide 2.5-15mg) received FDA approval for chronic weight management in November 2023. It contains the same tirzepatide molecule as Mounjaro but carries the chronic-weight-management indication.

Source: FDA approval data — Zepbound® prescribing information

How does this medication work?

Zepbound (tirzepatide) activates both GIP and GLP-1 receptors to suppress appetite, enhance fat metabolism, and slow digestion.

Zepbound leverages tirzepatide's dual-agonist mechanism, simultaneously targeting GIP and GLP-1 receptors to suppress appetite, slow gastric emptying, enhance fat metabolism, and improve insulin sensitivity. The GLP-1 component reduces hunger and food intake by acting on the brain's satiety centers, while the GIP component improves how the body metabolizes and stores fat. Together, these two hormonal pathways create a broad metabolic effect. This dual action distinguishes tirzepatide's mechanism from GLP-1-only medications.

What is it FDA-approved for?

FDA-approved for chronic weight management (2023) in adults with obesity or overweight plus a comorbidity. The first dual GIP/GLP-1 agonist approved specifically for weight loss.

Zepbound is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. The SURMOUNT trial program -- one of the largest obesity drug development programs ever conducted -- provided the clinical evidence for this approval, demonstrating consistent and significant weight loss across diverse patient populations.

What are the key facts you should know?

Once-weekly injection, 2.5mg to 15mg dose range, FDA-approved for chronic weight management, manufactured by Eli Lilly.

Zepbound is available in six dose strengths -- 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg -- administered once weekly via a pre-filled injectable pen. It is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. Zepbound received FDA approval in November 2023 and became commercially available in early 2024.

Why choose this treatment?

Zepbound is the first dual GIP/GLP-1 agonist FDA-approved specifically for chronic weight management in eligible adults.

Zepbound® is FDA-approved specifically for chronic weight management in adults meeting the FDA-approved indication. Patients seeking the FDA-approved brand-name Zepbound® obtain it through a retail pharmacy. Weight Method does not dispense or prescribe brand-name Zepbound®. For patients who, after consultation with a Weight Method provider, choose compounded tirzepatide as part of a chronic-weight-management program, Weight Method dispenses compounded tirzepatide through U.S.-licensed 503A compounding pharmacies at $329/month all-inclusive (medication, licensed-provider evaluation, ongoing provider access, dose management, and home shipping). Compounded tirzepatide is not FDA-approved.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Starting at$199/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Compounded semaglutide. Once-weekly subcutaneous injection.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Zepbound and Mounjaro both contain the same active ingredient -- tirzepatide -- manufactured by Eli Lilly, but they are approved for different indications. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved specifically for chronic weight management. The dose strengths and escalation schedules are identical. Your Weight Method provider will prescribe the appropriate formulation based on your health profile and goals.

Zepbound is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in eligible adults with obesity or overweight plus a weight-related comorbidity. Individual outcomes vary and depend on adherence, starting weight, diet, and activity level. Your Weight Method provider will set expectations for your individualized compounded tirzepatide plan during your consultation.

Zepbound (tirzepatide) and Wegovy (semaglutide) are both FDA-approved for chronic weight management. They work through different mechanisms: Zepbound's tirzepatide targets both the GIP and GLP-1 receptors, while Wegovy's semaglutide targets the GLP-1 receptor only. Your Weight Method provider will recommend the appropriate compounded medication for your specific situation.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain. In SURMOUNT trials, approximately 25-30% of participants experienced nausea, most commonly during dose escalation. Most side effects are mild to moderate and resolve within a few weeks. Serious but rare side effects include pancreatitis, gallbladder issues, and allergic reactions. Your provider will monitor you throughout treatment.

No. Weight Method does not dispense or prescribe brand-name Zepbound®. Our prescribing providers issue patient-specific prescriptions for compounded tirzepatide, dispensed by U.S.-licensed 503A compounding pharmacies. Weight Method's compounded tirzepatide program is $329/month all-inclusive (medication, licensed-provider evaluation, ongoing provider access, dose management, and home shipping). Compounded tirzepatide is not FDA-approved.

You may be eligible for Zepbound if you have a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea. You must be 18 or older and not pregnant or breastfeeding. Take the Weight Method quiz to check your eligibility in under two minutes.

Yes. Many patients switch from semaglutide to tirzepatide to achieve greater weight loss or break through a plateau. Your Weight Method provider will manage the transition, typically starting at a lower tirzepatide dose (2.5mg) and escalating gradually. There is no mandatory washout period, and your provider will determine the optimal timing and starting dose based on your current treatment.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Zepbound

Zepbound Side EffectsZepbound ResultsZepbound Dosingtirzepatide Dosage Calculator

Generic Medication

Tirzepatide

Other Tirzepatide Brands

MounjaroTirzepatide

Compare Zepbound

Mounjaro vs ZepboundWegovy vs ZepboundOzempic vs Zepbound

Zepbound by State

Zepbound in AlabamaZepbound in AlaskaZepbound in ArizonaZepbound in ArkansasZepbound in CaliforniaZepbound in Colorado